Geron Corp (GERN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.01 (+0.25%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Geron Corp (GERN)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Key Insights

Critical company metrics and information
  • Share Price

    $4.03
  • Market Cap

    $2.44 Billion
  • Total Outstanding Shares

    604.50 Million Shares
  • Total Employees

    141
  • Dividend

    No dividend
  • IPO Date

    July 31, 1996
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.geron.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$45.08 Million
Net Cash Flow From Financing Activities, Continuing$201.49 Million
Net Cash Flow$30.95 Million
Net Cash Flow From Operating Activities$-215.61 Million
Net Cash Flow From Operating Activities, Continuing$-215.61 Million
Net Cash Flow From Investing Activities, Continuing$45.08 Million
Net Cash Flow From Financing Activities$201.49 Million
Net Cash Flow, Continuing$30.95 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-201.19 Million
Benefits Costs and Expenses$175.96 Million
Other Operating Expenses$182.34 Million
Income/Loss From Continuing Operations After Tax$-201.19 Million
Diluted Average Shares$1.30 Billion
Interest Expense, Operating$12.12 Million
Net Income/Loss$-201.19 Million
Operating Income/Loss$-207.97 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Depreciation and Amortization$518000.00
Net Income/Loss Available To Common Stockholders, Basic$-201.19 Million
Basic Earnings Per Share$0.32
Diluted Earnings Per Share$0.32
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Costs And Expenses$232.44 Million
Net Income/Loss Attributable To Parent$-201.19 Million
Revenues$29.48 Million
Operating Expenses$237.45 Million
Basic Average Shares$1.30 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Fixed Assets$1.59 Million
Equity Attributable To Parent$292.28 Million
Noncurrent Assets$46.89 Million
Liabilities And Equity$444.95 Million
Other Non-current Assets$45.30 Million
Assets$444.95 Million
Inventory$20.28 Million
Accounts Payable$13.73 Million
Current Liabilities$137.93 Million
Other Current Assets$377.77 Million
Wages$15.18 Million
Noncurrent Liabilities$14.73 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$109.02 Million
Current Assets$398.06 Million
Equity$292.28 Million
Liabilities$152.67 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.